BridgeBio is significantly boosted its development of the new therapy for amyloid heart disease, leveraging the investigational drug. Initial clinical results suggests potential outcomes for those suffering by the https://biotech680230.blazingblog.com/42154382/company-progresses-attr-cm-treatment-using-attruby